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Abstract: 
Flavonolignans from milk thistle (Silybum marianum) have been investigated for their cellular 
modulatory properties, including cancer chemoprevention and hepatoprotection, as an extract 
(silymarin), as partially purified mixtures (silibinin and isosilibinin), and as pure compounds (a 
series of seven isomers). One challenge with the use of these compounds in vivo is their 
relatively short half-life due to conjugation, particularly glucuronidation. In an attempt to 
generate analogues with improved in vivo properties, particularly reduced metabolic liability, a 
semi-synthetic series was prepared in which the hydroxy groups of silybin B were alkylated. A 
total of five methylated analogues of silybin B were synthesized using standard alkylation 
conditions (dimethyl sulfate and potassium carbonate in acetone), purified using preparative 
HPLC, and elucidated via spectroscopy and spectrometry. Of the five, one was monomethylated 
(3), one was dimethylated (4), two were trimethylated (2 and 6), and one was tetramethylated 
(5). The relative potency of all compounds was determined in a 72 h growth-inhibition assay 
against a panel of three prostate cancer cell lines (DU-145, PC-3, and LNCaP) and a human 
hepatoma cell line (Huh7.5.1) and compared to natural silybin B. Compounds also were 
evaluated for inhibition of both cytochrome P450 2C9 (CYP2C9) activity in human liver 
microsomes and hepatitis C virus infection in Huh7.5.1 cells. The monomethyl and dimethyl 
analogues were shown to have enhanced activity in terms of cytotoxicity, CYP2C9 inhibitory 
potency, and antiviral activity (up to 6-fold increased potency) compared to the parent 
compound, silybin B. In total, these data suggested that methylation of flavonolignans can 
increase bioactivity. 
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1. Introduction 
Our research team has been studying the chemopreventive properties of a series of 
flavonolignans isolated from an extract (termed ‘silymarin’)1 of milk thistle [Silybum 
marianum (L.) Gaertn. (Asteraceae)]. 2, 3, 4, 5, 6,7 and 8 In vitro and human tumor xenograft 
anticancer activity of the commercial extracts, silymarin and silibinin, has been demonstrated in 
models of prostate, colon, and breast cancer. The extracts, and a subset of pure compounds 
derived therefrom, have been studied most extensively in prostate carcinoma cell lines, where 
they exhibit antiproliferative and pro-apoptotic activity via inhibition of expression of cyclins 
and cyclin-dependent kinases, induction of p21 and p27, degradation of androgen receptor, and 
activation of caspase-3 and caspase-9. 2, 3, 4, 5, 6, 7 and 8 Studies on the natural products chemistry of 
these compounds led to the gram-scale isolation of the flavonolignans, 9 which consist of a series 
of seven diastereo or constitutional isomers, and the isolation and identification of two new 
minor analogs. 10 Besides chemoprevention, some of these materials have been evaluated as 
inhibitors of cytochrome P450 2C9 (CYP2C9) 11 activity and activities associated with 
hepatoprotection. 12, 13, 14 and 15 
A challenge of working with milk thistle products has been translating the results from in vitro 
studies to the clinic, likely due to suboptimal pharmacokinetic characteristics of the 
compounds.16 The pharmacokinetics of unconjugated and conjugated (sulfated and 
glucuronidated) flavonolignans from milk thistle were examined after oral administration of up 
to 700 mg/day silymarin, and 28% and 55% of the total silymarin compounds in plasma were 
found as sulfate and glucuronide conjugates, respectively, after 1–3 h.17 Even with doses of 
13 g/day with a silibinin derived product in clinical studies by Flaig et al.,18 a major challenge to 
in vivo activity was extensive conjugation at phenolic positions. Conversely, these same phenolic 
moieties may present opportunities for the semi-synthetic modification of milk thistle 
compounds, if those that are or are not key for biological activity could be identified. 
Other research groups have probed the semisynthesis of analogues of silibinin19 and 20 (a 1:1 
mixture of silybin A and silybin B)1 and/or 2,3-dehydrosilybin.21 and 22 The present semisynthetic 
studies were designed with two central goals. The primary chemistry goal was to determine 
which methylated analogues could be generated readily using a straightforward alkylation 
procedure. For this, selectivity was not critical, as it was desirable to examine the various 
permutations of single-, double-, triple-, and tetra-methylated silybin B analogues. The primary 
pharmacology goal was to determine how these structural variations affected the antiproliferative 
activity of silybin B (1). A secondary pharmacology goal was to examine the compounds for 
inhibition of CYP2C9 activity and of antiviral activity against hepatitis C virus (HCV). For the 
synthetic experiments, 1 was utilized as a representative flavonolignan, since it is a major 
component of both silibinin and silymarin,2 there was an ample supply of >98% pure material on 
the gram scale available, and it was the easiest of the seven flavonolignans to 
purify.9 Compounds that were monomethylated or dimethylated were more potent than 1, with 
the most potent being the dimethylated analogue (compound 4; approximately 6 times more 
active). These data suggested that alkylation of the phenolic moieties of the flavonolignans 
presents a strategy for their continued exploration. 
2. Results and discussion 
2.1. Synthesis and isolation 
Silybin B (1) starting material was isolated in >98% purity from milk thistle extract (silymarin) 
as described in detail previously.9 Methylated analogues of 1 were prepared in a manner similar 
to that of Dzubak and colleagues;22 however, those researchers used a mixture of silybin A and 
silybin B (1) (often termed silibinin),1 and thus their analogues were generated as diastereomeric 
mixtures.22 Briefly, dimethyl sulfate was added to a solution of 1 and potassium carbonate in 
anhydrous acetone. The mixture was heated at reflux for 30 min, cooled to room temperature, 
acidified with dilute hydrochloric acid, and extracted with ethyl acetate. The organic extracts 
were combined and concentrated to dryness under reduced pressure. The resulting oil was 
purified using RP-HPLC to yield five major products (compounds 2–6; Fig. 1) in greater than 
95% purity as measured by analytical RP-HPLC (Fig. S1; the numbering of the compounds 
corresponds to their elution order). 
 
Figure 1. Structures of silybin B (1) and the methylated analogues 2–6. 
2.2. Structure elucidation 
The structures of the five methylated analogues of silybin B (1) were elucidated using a suite of 
NMR experiments in conjunction with HRMS data. Table 1 and Table 2 summarize the 1H 
and 13C NMR data, respectively, for compounds 2–6 in comparison to the well established data 
for 1. The supplement includes the 1H and 13C NMR data as stack plots (Figs. S2 and S3, 
respectively) and illustrates the ECD data (Fig. S4), which verified that all analogues retained the 
configuration of 1. 
Table 1.1H NMR data for silybin B (1) and methylated analogues 2–6 acquired in DMSO-d6 
Position 1δH (J in Hz) 2δH (J in 
Hz) 
3δH (J in 
Hz) 
4δH (J in 
Hz) 
5δH (J in 
Hz) 
6δH (J in 
Hz) 
2 5.08, d (12) 5.05, d 
(11) 
5.13, d 
(12) 
5.13, d 
(12) 
5.04, d 
(12) 
5.13, d 
(12) 
3 4.61, d (12) 4.38, d 
(11) 
4.66, br. 
d. 
4.66, dd 
(12, 7) 
4.66, dd 
(12, 7) 
4.65, d 
(12) 
6 5.92, s 6.22, d (2) 6.11, s 6.11, d (2) 6.22, d 
(2) 
6.10, s 
8 5.88, s 6.18, d (2) 6.09, s 6.09, d (2) 6.18, d 
(2) 
6.08, s 
2′ 7.08, d (2) 7.08, d (2) 7.09, d (2) 7.10, d (2) 7.07, d 
(2) 
7.11, d (2) 
Position 1δH (J in Hz) 2δH (J in 
Hz) 
3δH (J in 
Hz) 
4δH (J in 
Hz) 
5δH (J in 
Hz) 
6δH (J in 
Hz) 
5′ 6.98, d (9) 6.97, d (9) 6.98, d (9) 6.97, d (9) 6.99, d 
(9) 
7.01, d (9) 
6′ 7.01, dd (9, 2) 7.02, dd 
(9, 2) 
7.03, dd 
(9, 2) 
7.03, dd 
(9, 2) 
7.09, dd 
(9, 2) 
7.04, dd 
(9, 2) 
α 4.17, ddd (8, 
5, 2) 
4.19, ddd 
(8, 4, 2) 
4.17, ddd 
(8, 5, 2) 
4.19, ddd 
(8, 4, 2) 
4.36, m 4.38, ddd 
(8, 5, 2) 
β 4.92, d (8) 4.97, d (8) 4.91, d (8) 4.97, d (8) 4.94, d 
(8) 
4.95, d (8) 
γ 3.54, ddd (11, 
5, 2); 3.35, 
ddd (11, 5, 5) 
3.82, m; 
3.74, m 
3.54, m; 
3.35, m 
3.55, m; 
3.35, m 
3.82, m; 
3.74, m 
3.81, m; 
3.76, m 
2″ 7.02, d (2) 7.01, d (2) 7.02, d (2) 7.04, d (2) 7.05, d 
(2) 
7.06, d (2) 
5″ 6.81 d, (8) 6.98, d (9) 6.80, d (8) 6.98, d (8) 6.97, d 
(8) 
6.99, d (8) 
6″ 6.87, dd (8, 2) 6.99, dd 
(9, 2) 
6.86, dd 
(8, 2) 
6.99, dd 
(8, 2) 
6.98, dd 
(8, 2) 
7.00, dd 
(8, 2) 
3-OH — — — 5.88, d (7) 5.88, d 
(7) 
— 
5-OH 11.90, s — — — — — 
5-OCH3 — 3.80, s — — 3.80, s — 
7-OCH3 — 3.80, s 3.78, s 3.78, s 3.80, s 3.78, s 
3″-
OCH3 
3.78, s 3.77, s 3.77, s 3.77, s 3.78, s 3.78, s 
4″-
OCH3 
— 3.76, s — 3.76, s 3.77, s 3.77, s 
Position 1δH (J in Hz) 2δH (J in 
Hz) 
3δH (J in 
Hz) 
4δH (J in 
Hz) 
5δH (J in 
Hz) 
6δH (J in 
Hz) 
γ-OCH3 — — — — 3.22, s 3.22, s 
 
Table 2.13C NMR data for silybin B (1) and methylated analogues 2–6 acquired in DMSO-d6 
Position 1δC, mult. 2δC, mult. 3δC, mult. 4δC, mult. 5δC, mult. 6δC, mult. 
2 82.5, CH 82.1, CH 82.6, CH 82.9, CH 82.1, CH 82.6, CH 
3 71.5, CH 72.5, CH 71.5, CH 71.6, CH 72.5, CH 71.5, CH 
4 197.8, C 190.2, C 198.4, C 198.4, C 190.2, C 193.3, C 
5 163.3, C 161.6, C 163.0, C 163.0, C 161.6, C 162.4, C 
6 96.1, CH 92.9, CH 94.9, CH 94.9, CH 92.9, CH 93.8, CH 
7 166.8, C 165.7, C 167.6, C 167.6, C 165.7, C 167.6, C 
8 95.0, CH 93.6, CH 93.8, CH 93.8, CH 93.6, CH 95.0, CH 
9 162.5, C 163.7, C 162.4, C 162.4, C 163.7, C 163.6, C 
10 100.5, C 103.5, C 101.4, C 101.4, C 103.5, C 101.4, C 
1′ 130.1, C 130.3, C 129.9, C 130.0, C 130.4, C 130.2, C 
2′ 116.7, CH 116.5, CH 116.6, CH 116.6, CH 116.6, CH 116.8, CH 
3′ 143.2, C 143.1, C 143.2, C 143.2, C 143.1, C 143.1, C 
4′ 143.6, C 143.5, C 143.7, C 143.6, C 143.2, C 143.4, C 
5′ 116.4, CH 116.4, CH 116.4, CH 116.4, CH 116.4, CH 116.4, CH 
6′ 121.2, CH 121.0, CH 121.2, CH 121.0, CH 121.1, CH 121.3, CH 
α 78.1, CH 78.0, CH 78.1, CH 78.1, CH 75.7, CH 75.8, CH 
Position 1δC, mult. 2δC, mult. 3δC, mult. 4δC, mult. 5δC, mult. 6δC, mult. 
β 75.9, CH 75.7, CH 75.8, CH 76.0, CH 76.4, CH 76.4, CH 
γ 60.2, CH2 60.1, CH2 60.2, CH2 60.1, CH2 70.9, CH2 70.9, CH2 
1″ 127.5, C 129.0, C 127.5, C 129.0, C 128.7, C 128.7, C 
2″ 111.6, CH 111.1, CH 111.6, CH 111.7, CH 111.0, CH 111.0, CH 
3″ 147.6, C 149.1, C 147.6, C 149.1, C 149.1, C 149.2, C 
4″ 147.0, C 148.8, C 147.0, C 148.8, C 148.8, C 148.8, C 
5″ 115.3, CH 111.5, CH 115.3, CH 116.2, CH 111.5, CH 111.5, CH 
6″ 120.5, CH 120.2, CH 120.5, CH 120.5, CH 120.2, CH 120.2, CH 
5-OCH3 — 55.9, CH3 — — 56.0, CH3 — 
7-OCH3 — 55.9, CH3 56.0, CH3 56.0, CH3 55.8, CH3 56.0, CH3 
3″-OCH3 55.7, CH3 55.6, CH3 55.7, CH3 55.6, CH3 55.6, CH3 55.6, CH3 
4″-OCH3 — 55.5, CH3 — 55.4, CH3 55.5, CH3 55.5, CH3 
γ-OCH3 — — — — 58.6, CH3 58.6, CH3 
 
Of the five compounds, one was monomethylated (3), one was dimethylated (4), two were 
trimethylated (2and 6), and one was tetramethylated (5). The signals for methoxy groups in 
the 1H and 13C NMR spectra (i.e.δH 3.2–3.8 and δC 55–59, respectively) helped identify the 
number of methyl groups incorporated in the structure of 1; the HRMS data served to verify the 
number of additional methyl groups. For example, compound 2, which was the major product of 
the reaction, was 5,7,4″-tri-O-methylsilybin B (2). Key HMBC signals that established the 
positions of the methyl moieties included correlations from OCH3-5 to C-5, from OCH3-7 to C-7, 
and from OCH3-4″ to C-4″ ( Fig. 2). HRESIMS data confirmed the addition of three methyl 
groups in the structure (m/z 547.1579 [M+Na]+, calcd for C28H28O10Na, 547.1580). The other 
analogues displayed similar HMBC correlations, thereby establishing the structures of 7-O-
methylsilybin B (3), 7,4″-di-O-methylsilybin B (4), 5,7,4″,γ-tetra-O-methylsilybin B (5), and 
7,4″,γ-tri-O-methylsilybin B (6). As with compound 2, these structures were supported by 
HRMS data (see Section 4). 
 
Figure 2. Key HMBC correlations for the major product of the reaction, 5,7,4″-tri-O-
methylsilybin B (2). The other analogues displayed similar data, depending on the number of 
methyl groups incorporated. 
2.3. Bioassay results 
2.3.1. Antiproliferative assays 
The potency of the analogues (2–6) was determined in a 72 h growth-inhibition assay relative to 
silybin B (1) and against a panel of three prostate cancer cell lines (DU-145, PC-3, and LNCaP) 
and a human hepatoma cell line (Huh7.5.1; Table 3). For inhibition of prostate cancer cells, the 
most potent analogue (∼6-fold increased potency) was compound 4, corresponding to 
methylation of the phenolic moieties at positions 7 and 4″, yielding IC50 values that were 
⩽10 μM against two of the cell lines (DU-145 and PC-3). The next most potent analogue, 
having a single methyl group at the 7 position (3), was approximately a factor of two less active 
than 4. However, all of the compounds were equal to or slightly more potent (up to 6-fold 
increased potency) than the parent (1; mean IC50 = 61.8 μM in DU-145 cells). Similarly, for 
inhibition of hepatoma cell growth, all of the methylated compounds were more potent than the 
parent. In particular, compounds 3 and 4were over 5-fold more potent than the parent (1). In sum 
total, these cytotoxicity data, regardless of cell type, suggested that modifications at any of the 
phenolic moieties could generate compounds that enhance the antiproliferative potency of silybin 
B (1). 
Table 3. Antiproliferative activity of silybin B (1) and analogues 2–6 against a panel of cell lines 
in culture 
Compound Mean IC50 values and standard deviations (μM) 
 
DU-145 PC-3 LNCaP Huh7.5.1 
1 61.8 ± 3.3 60.5 ± 4.3 69.6 ± 3.8 56.2 ± 2.8a 
2 46.9 ± 3.7 36.3 ± 3.7 40.7 ± 3.9 25.5 ± 1.8 
Compound Mean IC50 values and standard deviations (μM) 
 
DU-145 PC-3 LNCaP Huh7.5.1 
3 19.3 ± 3.4 16.9 ± 3.6 20.1 ± 3.7 13.3 ± 1.8 
4 10.0 ± 3.7 8.1 ± 3.5 11.3 ± 4.8 13.5 ± 1.8 
5 24.0 ± 4.3a 14.4 ± 4.4 30.1 ± 3.7 15.6 ± 1.8 
6 16.8 ± 3.9 21.9 ± 4.1 19.8 ± 4.8 ntb 
a The IC50 values and standard deviations for these points were estimated based on visual 
inspection of sigmoidal dose–response curves. 
b Not tested. 
2.3.2. Inhibition of CYP2C9 activity 
The inhibitory effects of four of the major compounds found in silymarin (silybin A, silybin B 
(1), isosilybin A, and isosilybin B) on the CYP2C9-mediated metabolism of (S)-warfarin were 
reported recently. 11 Silybin B (1) was the most potent of the four, with an IC50 value of 8.2 μ
M. 11 Accordingly, the CYP2C9 inhibitory potencies of the methylated analogues (2–5) were 
compared ( Fig. 3); compound 6 was not evaluated due to paucity of sample. With the exception 
of 5, all compounds inhibited CYP2C9 activity in a concentration-dependent manner (1 vs 10 μ
M). Compound 2 was less potent than 1 at 100 μM, whereas compounds 3 and4, representing 
monomethylation at the 7-OH and dimethylation at the 7- and 4″-OH moieties, respectively, 
were more potent than 1, with activities below the limit of quantification when tested at 100 μ
M. These results suggested that despite increased cytotoxic potency, methylation of silybin B 
may modulate the clearance of drugs metabolized by CYP2C9. 
 
Figure 3. Effects of silybin B (1) and methylated analogues (2–5) on CYP2C9-mediated (S)-
warfarin 7-hydroxylation in human liver microsomes (HLM). Incubation mixtures consisted of 
HLM (0.1 mg/mL), (S)-warfarin (4 μM), silybin B or methylated analogue (1, 10, or 100 μM; 
open, solid, and hatched bars, respectively) and potassium phosphate buffer (100 mM, pH 7.4). 
Reactions were initiated by the addition of NADPH (1 mM) and were terminated after 30 min 
with ice-cold MeOH (2 volumes). Activity in the presence of vehicle control (0.75% MeOH, v/v) 
was 4.3 ± 0.26 pmol/min/mg microsomal protein. Bars and error bars denote means and SDs, 
respectively, of triplicate incubations. BLQ, below limit of quantification. ∗p<0.05, 1 versus 
10 μM; #p <0.05, 10 versus 100 μM; †p <0.05 versus silybin B at 100 μM (two-way ANOVA 
followed by Tukey’s test). 
2.3.3. Inhibition of hepatitis C virus (HCV) infection 
Figure 4 illustrates the antiviral profile of compounds 2–5 against HCV infection of human 
hepatoma Huh7.5.1 cells; compound 6 was not evaluated due to paucity of sample. Previous 
studies indicated that the IC50 value for inhibition of HCV infection by silybin B (1) was 
approximately 40 to 80 μM.13 The tested analogues of 1 inhibited HCV infection at lower 
concentrations, and the dimethyl analogue 4 was the most potent. These data indicated that 
methylated silybin B analogues were more active than 1 as antivirals in the following order: 
dimethyl (4) > monomethyl (3) > tetramethyl (5) > trimethyl (2) > 1. It was intriguing that both 
the cytotoxicity and antiviral activities were enhanced by methylation, even though the antiviral 
testing was conducted at non-toxic concentrations of the analogues. 
 
Figure 4. Methylated analogues (2–5) were more potent than silybin B (1) in blocking HCV 
infection. Human hepatoma Huh7.5.1 cells were infected with HCV in the presence of increasing 
concentrations of analogues for 72 h before cytoplasmic proteins were extracted and HCV NS5A 
and core proteins detected by Western blot. Detection of cellular actin protein served as a loading 
control. The concentrations selected for testing were nontoxic: compound 2: 1.9, 9.4, 18.9 μM; 
compound 3: 2.0, 10.1 μM; compound 4: 1.9, 9.7 μM; compound 5: 1.8, 9.2 μM. D refers to 
the DMSO solvent control. 
3. Conclusion 
In summary, a series of methylated analogues of silybin B (1) were synthesized; some of these 
analogues have been reported previously, albeit in the context of diastereomeric mixtures with 
silybin A analogues.22 In the case of the dimethyl (4) and monomethyl (3) analogues, and 
irrespective of the biological assay, the bioactivity increased relative to 1 in terms of growth 
inhibition of prostate and liver cancer cells, inhibition of CYP2C9 activity, and antiviral activity 
against HCV. These data suggest the feasibility of retaining and even enhancing the bioactivity 
of silymarin-derived compounds, and provides a rationale for methylating other isomers to test in 
anticancer, antiviral, metabolic, and pharmacologic assays. Ultimately, such studies could 
provide valuable structure–activity relationships for delineating the mechanisms of action of 
flavonolignans, which could aid in understanding how these compounds act in many 
inflammatory disease states. 
4. Experimental 
4.1. General experimental methods 
Optical rotation, UV, and IR data were acquired on a Rudolph Research Autopol® III 
polarimeter, a Varian Cary 3 UV–Vis spectrophotometer, and a Nicolet Avatar 360 FT-IR, 
respectively. Circular dichroism spectra were obtained from an Aviv Stopped Flow Model 202 
circular dichroism spectrometer. All NMR experiments were acquired on a Varian Unity 
INOVA-500 instrument using a 5 mm broad-band inverse probe with z-gradient using DMSO-
d6. LRESIMS data were acquired using an API 150EX mass spectrometer. HRMS data were 
acquired on an Applied Biosystems 4700 TOF/TOF instrument operating in reflectron mode 
using 2,5 dihydroxybenzoic acid as the matrix. For those data, spectra were the average of 500–
1000 laser shots, and the mass values were the mean of five independent measurements. Some 
HRMS data were also acquired on a Thermo LTQ Orbitrap XL mass spectrometer equipped with 
an ESI source. Preparative HPLC was carried out on a Varian Prostar HPLC system equipped 
with Prostar 210 pumps and a 335 photodiode array detector (PDA), with data collected and 
analyzed using Galaxie Chromatography Data System software (version 1.9), using an ODS-A 
column (250 × 20 mm, i.d., 5 μm; YMC, Wilmington, NC) at a flow rate of 7 mL/min. This 
same system and software were used for analytical HPLC via an ODS-A column 
(150 × 4.6 mm, i.d., 5 μm) at a flow rate of 1 mL/min. 
4.2. Synthesis and purification 
Silybin B (1) was isolated in >98% purity from milk thistle extract (silymarin) as described in 
detail previously.9 Methylated analogs of 1 were prepared in a manner analogous to that of 
Dzubak and colleagues.22 Dimethyl sulfate (0.20 g, 1.55 mmol) was added to a solution 
of 1 (0.15 g, 0.31 mmol) and K2CO3 (0.35 g, 2.48 mmol) in anhydrous acetone (5 mL). The 
suspension was allowed to stir at reflux for 30 min and was then cooled to room temperature. 
The suspension was diluted with 1 N HCl (5 mL) and extracted with EtOAc (3 × 5 mL). The 
organic extracts were combined, dried (MgSO4), and concentrated under reduced pressure to 
provide a brown oil (150 mg) as a mixture of methylated analogs. 
4.2.1. Purification 
The reaction product (150 mg) was dissolved in DMSO (500 μL) and purified via two separate 
rounds (∼75 mg/round) of RP-HPLC using a gradient that initiated with 60:40 MeOH:H2O and 
increased linearly to 70:30 MeOH:H2O over 60 min, where it was held isocratic for another 
40 min, to yield compounds 2(25.1 mg; 16.7%), 3 (10.6 mg; 7.1%), 4 (14.5 mg; 
9.7%), 5 (12.0 mg; 8.0%), and 6 (2.7 mg; 1.8%). 
4.2.1.1. Silybin B (1) 
The physical properties of 1 were described in detail previously.23 and 24 
4.2.1.2. 5,7,4″-Tri-O-methylsilybin B (2) 
White solid (25.1 mg, yield 16.7% w/w); t  R 7.65 min in 60:40 → 100:0 MeOH–H2O over 
15 min with the ODS A column;  −10.67 (c 0.6, MeCN); UV (MeOH) λmax (log ε) 283 
(5.25), 205 (5.88) nm; CD (MeOH) λext(Δε) 333 (+3.3), 293 (−19.7), 233 (+21.6) nm; IR 
(KBr) νmax 3438, 2934, 1672, 1606, 1571, 1508, 1422, 1257, 1214, 1106, 1021, 985, 812 cm−
1; 1H and 13C NMR data, see Table 1 and Table 2; HMBC data, H-2 → C-3, 4, 9, 1′, 2′, 6′; 
H-3 → C-2, 4, 10, 1′; H-6 → C-5, 7, 8, 10; H-8 → C-6, 7, 9, 10; H-2′ → C-2, 1′, 3′, 4′; 
H-5′ → C-1′, 3′, 4′, 6′; H-6′ → C-2, 1′, 2′, 4′, 5′; H-α → C-β, γ, 4′, 1″; 
H-β → C-α, γ, 3′, 1″, 2″, 6″; H2-γ → C-α, β; H-2″ → C-1″, 3″, 4″, 6″; H-5
″ → C-1″, 3″, 4″, 6″; H-6″ → C-β, 1″, 2″, 4″, 5″; OCH3-3″ → C-3″; OCH3-
5 → C-5; OCH3-7 → C-7; OCH3-4″ → C-4″; HRESIMS m/z 547.1579 [M+Na]+ (calcd for 
C28H28O10Na, 547.1580). 
4.2.1.3. 7-O-Methylsilybin B (3) 
White solid (10.6 mg, yield 7.1% w/w); t  R 7.88 min in 60:40 → 100:0 MeOH–H2O over 15 min 
with the ODS A column;  +2.67 (c 0.5, MeOH); UV (MeOH) λmax (log ε) 287 (5.28), 204 
(5.93) nm; CD (MeOH) λext (Δε) 333 (+3.7), 295 (−15.5), 234 (+12.4) nm; IR (KBr) ν
max 3400, 2936, 1668, 1606, 1571, 1508, 1422, 1258, 1214, 1105, 1021, 986, 813 cm−1; 1H 
and 13C NMR data, see Table 1 and Table 2; HMBC data, H-2 → C-3, 4, 9, 1′, 2′, 6′; H-
3 → C-2, 4, 10, 1′; H-6 → C-5, 7, 8, 10; H-8 → C-6, 7, 9, 10; H-2′ → C-2, 1′, 3′, 4′; H-
5′ → C-1′, 3′, 4′, 6′; H-6′ → C-2, 1′, 2′, 4′, 5′; H-α → C-β, γ, 4′, 1″; H-
β → C-α, γ, 3′, 1″, 2″, 6″; H2-γ → C-α, β; H-2″ → C-1″, 3″, 4″, 6″; H-5
″ → C-1″, 3″, 4″, 6″; H-6″ → C-β, 1″, 2″, 4″, 5″; OCH3-3″ → C-3″; OCH3-
7 → C-7; HRESIMS m/z 519.1271 [M+Na]+ (calcd for C26H24O10Na, 519.1267). 
4.2.1.4. 7,4″-Di-O-methylsilybin B (4) 
White solid (14.5 mg, yield 9.7% w/w); t  R 9.17 min in 60:40 → 100:0 MeOH–H2O over 15 min 
with the ODS A column;  +8.77 (c 0.7, MeOH); UV (MeOH) λmax (log ε) 286 (5.26), 205 
(5.93) nm; CD (MeOH) λext (Δε) 335 (+5.1), 294 (-21.8), 233 (+17.7) nm; IR (KBr) ν
max 3432, 2937, 1670, 1606, 1572, 1508, 1422, 1258, 1214, 1105, 1021, 986, 811 cm−1; 1H 
and 13C NMR data, see Table 1 and Table 2; HMBC data, H-2 → C-3, 4, 9, 1′, 2′, 6′; H-
3 → C-2, 4, 10, 1′; H-6 → C-5, 7, 8, 10; H-8 → C-6, 7, 9, 10; H-2′ → C-2, 1′, 3′, 4′; H-
5′ → C-1′, 3′, 4′, 6′; H-6′ → C-2, 1′, 2′, 4′, 5′; H-α → C-β, γ, 4′, 1″; H-
β → C-α, γ, 3′, 1″, 2″, 6″; H2-γ → C-α, β; H-2″ → C-1″, 3″, 4″, 6″; H-5
″ → C-1″, 3″, 4″, 6″; H-6″ → C-β, 1″, 2″, 4″, 5″; OCH3-3″ → C-3″; OCH3-
7 → C-7; OCH3-4″ → C-4″; HRESIMSm/z 533.1429 [M+Na]+ (calcd for C27H26O10Na, 
533.1424). 
4.2.1.5. 5,7,4″,γ-Tetra-O-methylsilybin B (5) 
White solid (12.0 mg, yield 8.0% w/w); t  R 9.91 min in 60:40 → 100:0 MeOH–H2O over 15 min 
with the ODS A column;  −6.18 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 285 (5.26), 205 
(5.91) nm; CD (MeOH) λext (Δε) 334 (+3.1), 294 (−16.2), 233 (+15.5) nm; IR (KBr) ν
max 3424, 2936, 1670, 1606, 1571, 1508, 1422, 1257, 1214, 1106, 986, 812 cm−1; 1H and 13C 
NMR data, see Table 1 and Table 2; HMBC data, H-2 → C-3, 4, 9, 1′, 2′, 6′; H-3 → C-2, 4, 
10, 1′; H-6 → C-5, 7, 8, 10; H-8 → C-6, 7, 9, 10; H-2′ → C-2, 1′, 3′, 4′; H-5′ → C-1
′, 3′, 4′, 6′; H-6′ → C-2, 1′, 2′, 4′, 5′; H-α → C-β, γ, 4′, 1″; H-β → C-α, 
γ, 3′, 1″, 2″, 6″; H2-γ → C-α, β; H-2″ → C-1″, 3″, 4″, 6″; H-5″ → C-1″, 3
″, 4″, 6″; H-6″ → C-β, 1″, 2″, 4″, 5″; OCH3-3″ → C-3″; OCH3-5 → C-5; OCH3-
7 → C-7; OCH3-4″ → C-4″; OCH3-γ → C-γ; HRESIMS m/z 561.1746 [M+Na]+ (calcd for 
C29H30O10Na, 561.1737). 
4.2.1.6. 7,4″,γ-Tri-O-methylsilybin B (6) 
White solid (2.7 mg, yield 1.8% w/w); t  R 11.03 min in 60:40 → 100:0 MeOH–H2O over 15 min 
with the ODS A column;  +9.0 (c 0.05, MeOH); UV (MeOH) λmax (log ε) 286 (5.13), 205 
(5.86) nm; CD (MeOH) λext (Δε) 335 (+4.0), 294 (−19.7), 232 (+17.4) nm; IR (KBr) ν
max 3400, 2935, 1670, 1606, 1572, 1508, 1423, 1258, 1215, 1107, 1023, 951, 815 cm−1; 1H 
and 13C NMR data, see Table 1 and Table 2; HMBC data, H-2 → C-3, 4, 9, 1′, 2′, 6′; H-
3 → C-2, 4, 10, 1′; H-6 → C-5, 7, 8, 10; H-8 → C-6, 7, 9, 10; H-2′ → C-2, 1′, 3′, 4′; H-
5′ → C-1′, 3′, 4′, 6′; H-6′ → C-2, 1′, 2′, 4′, 5′; H-α → C-β, γ, 4′, 1″; H-
β → C-α, γ, 3′, 1″, 2″, 6″; H2-γ → C-α, β; H-2″ → C-1″, 3″, 4″, 6″; H-5
″ → C-1″, 3″, 4″, 6″; H-6″ → C-β, 1″, 2″, 4″, 5″; OCH3-3″ → C-3″; OCH3-
7 → C-7; OCH3-4″ → C-4″; OCH3-γ → C-γ; HRESIMS m/z 525.1740 [M+H]+ (calcd for 
C28H29O10, 525.1755). 
4.3. Biological assays 
4.3.1. Antiproliferative assay 
All compounds were tested for antiproliferative/cytotoxic activity against a panel of prostate 
cancer cell lines in culture using modifications of a published procedure2 that have been 
described in detail.10 The prostate cancer cell lines were obtained from the American Type 
Culture Collection (Manassas, VA): DU145 (HTB-81, an androgen-independent line derived 
from a central nervous system metastasis of prostate adenocarcinoma), PC-3 (CRL-1435, an 
androgen-independent line derived from a bone metastasis of prostate adenocarcinoma), and 
LNCaP (CRL-1740, an androgen-dependent line derived from a lymph node metastasis of 
prostate adenocarcinoma). All cell lines were cultured and maintained as described 
previously,2 with the recently noted modification for LNCaP.10 We also tested the 
antiproliferative/cytotoxic activity of compounds against a liver cancer cell line, 
Huh7.5.1.25 Briefly, 10,000 cells per well were plated in 96-well plates, and following overnight 
incubation, were incubated with increasing concentrations of compounds. Seventy-two hours 
later, cell viability was measured using the ATPlite kit, as described previously,13 and an 
IC50 was calculated by linear regression using GraphPad Prism. 
4.3.2. Inhibition of CYP2C9 activity 
Silybin B (1) and methylated analogues (2–5) were evaluated as inhibitors of CYP2C9 activity 
using (S)-warfarin and pooled human liver microsomes (HLM) as described 
previously. 11 Incubation mixtures consisted of HLM (0.1 mg/mL microsomal protein), (S)-
warfarin (4 μM), silybin B or methylated analogue (1, 10, or 100 μM), and potassium 
phosphate buffer (100 mM, pH 7.4). The CYP2C9 inhibitor sulfaphenazole (1 μM) was used as 
a positive control. Control incubation mixtures contained 0.75% MeOH (v/v) in place of silybin 
B/methylated analogue or sulfaphenazole. Incubation mixtures were analyzed for 7-
hydroxywarfarin by HPLC/MS–MS as described previously. 11 
All statistical analyses for this assay were conducted using SigmaStat (version 3.5; Systat 
Software, Inc., San Jose, CA). Data are presented as means ± SDs of triplicate incubations 
unless indicated otherwise. Concentration-dependent inhibition of silybin B and methylated 
analogs and comparisons between silybin B and methylated analogs were evaluated by two-way 
analysis of variance (ANOVA); post hoc comparisons were made using Tukey’s test when an 
overall difference resulted (p <0.05). 
4.3.3. Antiviral assays 
The antiviral activity of 1–5 was evaluated by choosing two concentrations that were non-toxic 
to cells. For this, 150,000 cells were plated in 12-well plates, and the next day, cells were 
infected with JFH-1, a HCV that grows well in Huh7.5.1 cells, at a multiplicity of infection of 
0.05 focus forming units per cell. Five hours post-infection, virus inocula were removed and 
replaced with fresh medium containing compounds. Protein lysates were harvested 72 h later, 
and HCV proteins were detected by Western blot analyses as described previously.13 
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